Global Immuno-Oncology Market to Experience 21% CAGR Backed by Personalized Medicine by 2030

The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and prevalence of cancer, advancements in immunotherapy and personalized medicine, favorable regulatory support and approvals, growing investment in cancer immunotherapy R&D, and expanding applications beyond traditional indications are some of the key factors driving the immuno-oncology market.

Immuno-oncology is a rapidly evolving field of cancer treatment that harnesses the body’s immune system to recognize, attack, and eliminate cancer cells. Unlike conventional therapies like chemotherapy and radiation, which directly target tumors, immuno-oncology therapies enhance the immune response against cancer. Key approaches include immune checkpoint inhibitors like PD-1/PD-L1 inhibitors, CAR-T cell therapy, bispecific antibodies, and cancer vaccines. These therapies have revolutionized cancer care by offering durable responses and improved survival in various malignancies. Ongoing research focuses on enhancing efficacy, overcoming resistance, and expanding applications to more cancer types through combination strategies and personalized medicine approaches.

Download a free sample report now 👉
https://meditechinsights.com/immuno-oncology-market/request-sample/

Increasing incidence and prevalence of cancer to propel market demand

The rising global incidence and prevalence of cancer are major drivers of the immuno-oncology market. With cancer being a leading cause of death worldwide, the demand for advanced, effective treatments is growing. . According to the WHO In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths, and the cancer cases are expected to increase significantly due to aging populations, lifestyle changes, and environmental factors. And, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated in 2022 The increasing cases of lung, colorectal, breast, and prostate cancers necessitate innovative therapies like immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Additionally, aging populations and lifestyle factors, such as smoking and obesity, contribute to higher cancer rates, further driving market expansion. As a result, pharmaceutical companies are investing heavily in immuno-oncology research to develop novel, targeted therapies that improve patient outcomes and survival rates.

Advancements in Immuno-Oncology Products: Emerging Therapies and Future Opportunities

The immuno-oncology field is advancing rapidly, with recent FDA approvals of bispecific T-cell engagers (BiTEs) and renewed interest in cancer vaccines, particularly mRNA-based therapies. Cell therapies, including CAR-T, are expanding into new indications and earlier treatment lines, such as non-Hodgkin’s lymphoma (NHL). Bispecific antibodies offer a promising approach by combining T-cell redirection with checkpoint modulation, potentially overcoming T-cell exhaustion. Additionally, dual-targeting immune checkpoint inhibitors (ICIs) may enhance efficacy over traditional combinations. Innovations in modifying the tumor microenvironment to counteract resistance present significant opportunities for the immuno-oncology market, driving new therapeutic strategies and improved patient outcomes.

Competitive Landscape Analysis

The global immuno-oncology market is marked by the presence of established and emerging market players such as Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., AstraZeneca, Sanofi, Moderna, Inc., GSK plc, AbbVie Inc., and Merck & Co., Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Download a sample report for in-depth competitive insights
https://meditechinsights.com/immuno-oncology-market/request-sample/

Market Segmentation

This report by Medi-Tech Insights provides the size of the global immuno-oncology market at the regional- and country-level from 2023 to 2030. The report further segments the market based on therapy type, cancer type, end user.

• Market Size & Forecast (2023-2030), By Therapy Type, USD Million
  • Immune Checkpoint Inhibitors (ICIs)
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Bispecific Antibodies
  • Monoclonal Antibodies
  • Oncolytic Viruses
  • Cytokine Therapy
  • Others
• Market Size & Forecast (2023-2030), By Cancer Type, USD Million
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Others
• Market Size & Forecast (2023-2030), By End User, USD Million
  • Hospitals & Cancer Treatment Centers
  • Specialty Clinics
  • Others
• Market Size & Forecast (2023-2030), By Region, USD Million
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
info@meditechinsights.com